Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies : Report of Three Cases of Breakthrough Infection
Data is limited on the immunogenicity of the COVID-19 two-vaccination series among patients with hematologic malignancies and current guidelines do not recommend routine monitoring for post-vaccine antibodies. However, we describe three patients who developed severe or critical COVID-19 infections six months after vaccination. This highlights the importance of routine testing of COVID-19 IgG Spike, semi-quantitative antibodies post-vaccination, particularly among immunocompromised patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Cancer control : journal of the Moffitt Cancer Center - 29(2022) vom: 01. Jan., Seite 10732748211070720 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pasikhova, Yanina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-spike igG |
|---|
| Anmerkungen: |
Date Completed 13.01.2022 Date Revised 13.01.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1177/10732748211070720 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335369340 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335369340 | ||
| 003 | DE-627 | ||
| 005 | 20231225225659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/10732748211070720 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335369340 | ||
| 035 | |a (NLM)35001670 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pasikhova, Yanina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies |b Report of Three Cases of Breakthrough Infection |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.01.2022 | ||
| 500 | |a Date Revised 13.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Data is limited on the immunogenicity of the COVID-19 two-vaccination series among patients with hematologic malignancies and current guidelines do not recommend routine monitoring for post-vaccine antibodies. However, we describe three patients who developed severe or critical COVID-19 infections six months after vaccination. This highlights the importance of routine testing of COVID-19 IgG Spike, semi-quantitative antibodies post-vaccination, particularly among immunocompromised patients | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hematologic Malignancies | |
| 650 | 4 | |a anti-spike igG | |
| 650 | 4 | |a mRNA vaccine | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Morrison, Austin R |e verfasserin |4 aut | |
| 700 | 1 | |a Katzman, Ju Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Syed, Misbahuddin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer control : journal of the Moffitt Cancer Center |d 1994 |g 29(2022) vom: 01. Jan., Seite 10732748211070720 |w (DE-627)NLM093817053 |x 1526-2359 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2022 |g day:01 |g month:01 |g pages:10732748211070720 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/10732748211070720 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2022 |b 01 |c 01 |h 10732748211070720 | ||